Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: July 30, 2025

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

SPD 2025: Bridging Research and Clinical Care

Renata Block, DMSc, MMS, PA-C, is a board-certified physician assistant and instructor at Rush University in Chicago, Illinois, a 

 editorial advisory board member, and the past president of the Society of Dermatology Physician Associates (SDPA) and the Illinois SDPA.

Videos

Explore career transitions in healthcare as PAs Renata Block, MMS, PA-C, and Jessica Dell'Aquila, MS, PA-C, share insights on professional growth and evolving roles in dermatology.

Derm Dispatch: Navigating Industry, Health Care, and Career Transitions as a PA

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

PC111, a novel therapy from Scinai, targets pemphigus vulgaris and SJS/TEN, offering rapid relief without immunosuppression.

New Research Reveals PC111's Potential to Revolutionize Pemphigus and SJS/TEN Treatment

The acne section is a comprehensive resource for clinical news and expert insights on acne. Read more at Dermatology Times.

Acne | Dermatology News & Insights | Dermatology Times

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

The potential for antibiotic resistance have caused some physicians to be wary of the drug class when prescribing an acne treatment regimen. Christopher Bunick, M.D., Ph.D., clears the air around antibiotic use for acne and discusses his research of narrow-spectrum antibiotics. 

The Cutaneous Connection- Episode 12: Antibiotics for Acne

Amir Karam, M.D., facial plastic surgeon, San Diego, Calif., explains the rising incidences of acne associated with face mask usage, otherwise known as maskne, as well as tips for prevention and treatment.

The Cutaneous Connection- Episode 10: Maskne

	Dermatology Times editorial advisor, Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, an active participant in the drug development process, discusses many of the important initial clinical observations and those that others have made over the years.

	Dermatology Times editorial advisor, Dr. Elaine Siegfried  discusses isotretinoin dosing and side effects with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania. Listen in and learn more.

	Dermatology Times editorial advisor, Dr. Elaine Siegfried and Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania discuss distinguishing sinus tracts or keratinous cysts from nodular areas of inflammation and techniques for treating via intralesional injection.

	Dermatology Times editorial advisor, Dr. Elaine Siegfried and Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania discuss whether a waiting period is necessary before treating acne scars and the questionable existence of pityrosporum folliculitis.

Dr. Jim Leyden, an active participant in isotretinoin's drug development process, discusses many of the important initial clinical observations and those that others have made over the years.

Isotretinoin's discovery and development series

Global acne burden in reproductive-age women has risen significantly, with greater increases expected by 2040.

Acne Burden is Growing in Young Women Across the World, New Study Finds

Discover how trifarotene, a novel retinoid, effectively addresses adult acne and its long-term effects, enhancing skin health and quality of life.

Integrating Trifarotene and Topical Retinoids Into Acne and Acne Sequelae Management

Discover the latest advancements in laser treatments for acne vulgaris, focusing on diverse skin types and effective solutions for acne skin of color.

Laser Therapy Gains Ground in Acne Management

SkinGPT by Haut.AI uses AI to visually simulate skin care results, empowering inclusive, personalized skin care and bridging clinical data with patient insight.

Beyond the Label: How AI Tools Such as SkinGPT Enhance Skin Care Understanding

Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.

Denifanstat Hits All Targets in Chinese Study

“I have been a dermatology PA for 23 years and have always prescribed isotretinoin and always will. It is absolutely a game-changing and life-changing medication for our patients with recalcitrant acne, or for scarring cystic acne,” said Shanna Miranti, MPAS, PA-C, in an interview at the 

Miranti, a board-certified physician assistant at Riverchase Dermatology in Naples, Florida, and a 

 editorial advisory board member, presented her tips for prescribing isotretinoin for patients as acne, as well as her involvement in the new 

SkinSync podcast with Elevate-Derm Alliance

At Elevate-Derm Summer, Shanna Miranti, MPAS, PA-C, highlighted practical strategies for isotretinoin prescribing, addressed the impact of iPLEDGE hurdles, and introduced SkinSync. 

 Demystifying Isotretinoin Prescriptions and Introducing the SkinSync Podcast 

Miranti’s presentation, “Lessons Learned in Acne,” focused on the underutilization of isotretinoin due to iPLEDGE-related challenges and emphasized why PAs and NPs should feel empowered to prescribe it. She reaffirmed her support for isotretinoin in cases of recalcitrant or scarring cystic acne and shared concern that administrative hurdles have discouraged many clinicians from using a medication she describes as life-changing for patients. Her goal of the presentation was to demystify the prescribing process and offer actionable guidance to increase comfort and confidence with initiating and managing isotretinoin therapy.

Miranti also provided a deep dive into implementation strategies to simplify isotretinoin prescribing. Her tips included workflow optimizations such as establishing protocols with specialty pharmacies and structuring office schedules to ensure timely monthly follow-ups. She also presented her personal set of “Accutane hacks,” a collection of practical tips clinicians can apply immediately to minimize friction points in isotretinoin management. For Miranti, her points were designed to improve access for patients while maintaining clinic efficiency, ensuring that patients who need isotretinoin are not left untreated due to logistical barriers.

Beyond her lecture, Miranti shared her excitement about co-hosting SkinSync, the first podcast created by dermatology PAs and NPs for their peers, produced by Elevate-Derm Alliance.

 The podcast aims to serve as a clinically relevant and relatable resource for PAs and NPs in dermatology. Additionally, reflecting on her experience at her first Elevate-Derm Summer Meeting, she praised the high-caliber education, noting the consistent value in each session and the opportunity to engage with dedicated and knowledgeable peers across the dermatology community.

Miranti S. Lessons learned in acne. Presented at: 2025 Elevate-Derm Summer Conference; July 24-28, 2025; Park City, UT.

Welcome to SkinSync: your dermatology update: Elevate-Derm Alliance. Accessed July 26, 2025. 

https://www.elevate-derm.com/skinsync-podcast

Shanna Miranti, a dermatology PA, advocates for the use of isotretinoin in treating recalcitrant and scarring cystic acne, despite challenges posed by iPLEDGE. At the 2025 Elevate-Derm Summer Conference, she shared strategies to simplify isotretinoin prescribing, including workflow optimizations and practical tips to enhance clinic efficiency. Miranti also introduced the SkinSync podcast, aimed at providing dermatology PAs and NPs with clinically relevant insights. She praised the educational value of the conference and the opportunity to connect with peers in the dermatology field.

At Elevate-Derm Summer, Shanna Miranti, MPAS, PA-C, highlighted practical strategies for isotretinoin prescribing, addressed the impact of iPLEDGE hurdles, and introduced the SkinSync podcast.

Demystifying Isotretinoin Prescriptions and Introducing the SkinSync Podcast

Sonia Batra, MD, shares effective summer acne solutions using lasers like Aerolase Neo Elite and AviClear, ensuring tailored care for optimal skin health.

Optimizing Acne Care in Summer with Advanced Laser Technologies

, Sonia Batra, MD, a board-certified dermatologist, micrographic dermatologic surgeon, and clinical assistant professor at the Keck School of Medicine of USC, shared valuable clinical insights into managing acne exacerbated by summer factors, such as heat, humidity, sweat, and increased sun exposure. Batra emphasized the role of emerging laser technologies in treating summer acne, challenging the conventional hesitation many clinicians feel about light-based therapies during peak UV seasons. She highlighted 2 devices that have proven particularly effective in her practice in Southern California.

The Aerolase Neo Elite is a 650-µs Nd:YAG laser that targets active inflammatory acne by thermally destroying 

 and reducing inflammation with little pain or downtime. Batra emphasized its tolerability, making it an excellent option for patients during summer, when adherence with multistep regimens can be lower. AviClear is a newer FDA-cleared laser that selectively targets sebaceous glands to reduce sebum production. Batra likens its long-term efficacy to a course of isotretinoin but without systemic adverse effects. With minimal downtime and only transient photosensitivity, it is a practical summer intervention, especially for high school and college students who can complete a treatment series before returning to school.

Batra encourages dermatologists to reframe summer as a strategic treatment window, particularly for younger patients with flexible availability. She also advocates for proactive communication. As summer acne often requires regimen modifications, she underscores the need for patients to check in regularly, especially when using photosensitizing agents such as retinoids or alpha and beta hydroxy acids.

“The one thing I always remind my staff is just to remind our patients that this is an open line of communication and everything needs to be tailored based on what's happening,” Batra said. “It's nice to keep those lines of communication open with patients and remind them that they can reach out depending on how their skin is responding and how we can help them adjust accordingly...we all know that what works for them in the winter does not always work in the summer and vice versa.”

Key patient education points include dispelling the myth that tanning improves acne and reinforcing that sunscreen is essential for long-term skin health, not a trigger. She advises clinicians to remain flexible with seasonal treatment plans and to consider nontraditional modalities like these summer-safe lasers as valuable tools in the acne management arsenal.

Ultimately, Batra’s message is clear: With open communication and strategic use of emerging therapies, clinicians can tailor summer acne care more effectively, improving outcomes and reducing treatment burden for patients.

Sonia Batra, MD, emphasizes the importance of managing summer acne exacerbated by heat, humidity, and sun exposure through innovative laser technologies. She highlights the Aerolase Neo Elite and AviClear lasers as effective treatments, offering minimal downtime and addressing acne without systemic side effects. Batra encourages dermatologists to view summer as an opportunity for strategic treatment, especially for younger patients, and stresses the importance of open communication and patient education. Dispelling myths about tanning and reinforcing sunscreen use are crucial for effective acne management during summer months.

Sonia Batra, MD, shares effective summer acne solutions using lasers such as Aerolase Neo Elite and AviClear, ensuring tailored care for optimal skin health.

Optimizing Acne Care in Summer With Advanced Laser Technologies

Explore insights on benzoyl peroxide and benzene risks in acne treatment from experts Renata Block, PA-C, and John Barbieri, MD, MBA.

Derm Dispatch: Navigating Benzoyl Peroxide Safety and Acne Treatment Advancements

 series, Renata Block, DMSc, MMS, PA-C, interviews John Barbieri, MD, MBA, a board-certified dermatologist at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, to discuss current concerns and insights regarding benzoyl peroxide (BPO), particularly its potential to form benzene.

Barbieri explained that benzene formation in BPO products is not due to contamination but rather a chemical instability, especially when exposed to heat. Patients can minimize this risk by storing BPO in cool environments and being cautious about delivery sources, particularly in hot climates. Although benzene is ubiquitous in our environment—from gasoline to pollution—some BPO products have been shown to exceed FDA limits, raising public concern.

“I'm not particularly concerned that people using benzoyl peroxide products are particularly at risk from an absolute risk standpoint...we all take risks in our daily lives,” Barbieri said. “So yes, there may be some very small incremental risk to products that have benzene in them over a long period of time, but that incremental risk seems to be quite small because it's hard to detect.”

Barbieri emphasized that the primary health concern is inhalational exposure, not dermal. Data so far, including his own research, have not shown elevated benzene blood levels or increased cancer risks among BPO users. However, he stresses the importance of reducing benzene presence to zero, as many products already achieve this, likely due to better formulation and manufacturing practices.

From a therapeutic standpoint, BPO remains a crucial acne treatment, especially for moderate to severe cases where its antibacterial and antibiotic resistance–preventing properties are unmatched. Barbieri discourages avoiding BPO entirely, as alternative treatments like oral antibiotics may pose greater risks. He encouraged clinicians to educate patients, evaluate adherence, and reassess diagnoses when BPO seems ineffective. The conversation also explored advancements in dermatology, including new oral IL-23 inhibitors for psoriasis.

“We're getting better treatment responses and [fewer adverse] effects, which is awesome. And I think the more that we can do that using medications that are going to be affordable and accessible, the better it will be for everyone,” Barbieri said.

Barbieri also gave a preview of his current research on spironolactone vs doxycycline in women with acne and app-based cognitive behavioral therapy for psoriasis. He highlights the critical intersection of dermatology and mental health, advocating for broader, more holistic care models. Finally, Barbieri underscored the value of interdisciplinary collaboration, peer education, and ongoing research to ensure both efficacy and safety in dermatologic therapies.

Benzoyl peroxide (BPO) products may form benzene due to chemical instability, not contamination, especially in heat. While benzene is common in the environment, some BPO products exceed FDA limits, raising concerns. However, the risk from BPO is minimal, with inhalational exposure being the primary concern. BPO remains vital for acne treatment, and avoiding it could lead to greater risks from alternatives. Advancements in dermatology, such as new IL-23 inhibitors for psoriasis, show promise. Interdisciplinary collaboration and holistic care models are essential for effective dermatologic therapies.

Explore insights on benzoyl peroxide and benzene risks in acne treatment from experts Renata Block, DMSc, MMS, PA-C, and John Barbieri, MD, MBA.

Iris Rubin, MD, highlights SEEN's science-backed hair care, designed for acne-prone skin, improving scalp health and reducing irritation.

How Hair Care is an Extension of Skin Care, According to Iris Rubin, MD

, Iris Rubin, MD, the founder and Chief Medical Officer of 

, dove deeper into the clinical efficacy and broader dermatological impact of her science-backed hair care brand that was developed with sensitive and acne-prone skin in mind.

“We really consider SEEN to be a science beauty crossover and more of a confidence brand,” Rubin said. “We're not a marketing story. We're about science.”

SEEN is recommended by over 5,000 dermatologists and estheticians and has been clinically tested in multiple studies published in the 

. One study evaluated SEEN in patients with mild to moderate dry, flaky scalp, showing that 93% experienced improvement after four weeks of use, despite SEEN not being medicated. Another six-month trial conducted by the head of the Harvard Hair Loss Clinic found a 44% reduction in hair shedding among women with female pattern hair loss using fragrance-free SEEN. Rubin attributes these outcomes to the removal of pore-clogging ingredients and common irritants, which can impact scalp and follicle health.

Rubin emphasizes that hair care is an extension of skin care, especially during Acne Awareness Month. She advised dermatologists to educate patients about how shampoos, conditioners, and styling products can exacerbate acne, even if a patient is diligent with their facial skincare. Non-comedogenic, clinically tested formulations are critical, and SEEN is one of the few brands that conducts finished-product testing to validate this. Further boosting patient accessibility, it is the first dermatologist-recommended hair care brand at Ulta.

“I wish it were as simple as I give you a list of 5 to 10 ingredients to avoid in hair care...But it actually turns out that there's a whole list of ingredients that can be comedogenic, and the amount of the ingredients and the way they combine also matter. So testing finished formulas is really essential to make sure that they're not pore-clogging,” Rubin said.

Looking ahead, SEEN plans to expand its offerings beyond hair care, with recent launches including a tear-free baby wash free of common irritants, along with a growing body care line. SEEN remains focused on addressing the unmet need for products that are both effective and skin-friendly, especially for individuals with acne, eczema, sensitive skin, and scalp concerns.

SEEN Hair Care, founded by Iris Rubin, MD, is a science-driven brand designed for sensitive and acne-prone skin. It is recommended by over 5,000 dermatologists and estheticians and has been clinically validated in studies published in the Journal of Drugs in Dermatology. SEEN's formulations, free from pore-clogging ingredients, have shown significant improvements in scalp and hair health. Rubin highlights the importance of non-comedogenic hair care products, especially during Acne Awareness Month, and emphasizes the need for finished-product testing. SEEN plans to expand its product line to include skin-friendly body care.

Iris Rubin, MD, reveals how her brand SEEN transforms hair products to combat acne, promoting clearer skin through innovative, skin-friendly formulations.

Acne Awareness Month: The Link Between Hair Care and Skin Health

As we celebrate Acne Awareness Month, Iris Rubin, MD, a Harvard-trained dermatologist and founder of 

, shares her unique journey in investigating the overlooked connection between hair products and acne-prone skin. Rubin, who previously led the Dermatologic and Vascular Laser Surgery Program at Children's National Medical Center in Washington, DC, never thought she would launch her own brand. Her clinical insight and personal experience with acne triggered by salon visits led to this revelation, sparking the creation of SEEN, a science-backed hair care line designed with skin in mind.

Through clinical research, Rubin discovered that even traditional shampoo and conditioner can leave residue on the skin for hours after use, contributing to skin conditions like acne, eczema, and irritation. She emphasized that because these products come into frequent contact with the face, back, and scalp, they should be considered part of a person’s overall skin care regimen. SEEN’s formulations are specifically designed to be noncomedogenic and safe for sensitive skin, filling a critical gap in both dermatological and consumer hair care.

SEEN is at the forefront of the “skinification” of hair care, a growing movement that applies dermatological science to hair product development. Although many brands incorporate skin care ingredients like hyaluronic acid or ceramides, SEEN advances this concept by also considering how hair products affect skin health. The line is formulated to promote not only healthy hair and scalp but also clearer, calmer skin.

Clinical results support SEEN’s efficacy. In a dermatologist-graded study of 27 patients with mild to moderate acne, 70% of those with body acne and 52% with facial acne showed improvement after using SEEN for 8 weeks. Although the products do not have any active medicated ingredients, the line also caters to patients with eczema, sensitive skin, or fragrance allergies. SEEN’s fragrance-free variants hold the National Eczema Association Seal of Acceptance and offer a rare solution for those needing gentle yet effective hair care.

“Anyone who has acne-prone skin really deserves to know the impact that hair products can have on the skin,” Rubin told 

. “At SEEN, we really are redefining and raising the bar on the ‘skinification of hair,’ not just using skin science to make hair products better...but also looking at the impact of hair products on the skin, face, and body.”

Iris Rubin, MD, a Harvard-trained dermatologist, founded SEEN Hair Care to address the overlooked link between hair products and acne-prone skin. Her clinical research revealed that traditional hair products can leave residue on the skin, contributing to acne and other skin conditions. SEEN's formulations are non-comedogenic and safe for sensitive skin, aligning with the "skinification" trend in hair care. Clinical studies show significant improvement in acne with SEEN's use. The brand also offers fragrance-free options approved by the National Eczema Association for sensitive skin.

, Julia Zimmermann, PD, PHD, a biophysicist, medical researcher, CEO of terraplasma, and Managing Director of hyped about science shared the journey behind the groundbreaking cold plasma skin care device, PHLAS. Originally developed through scientific research at the Max-Planck-Institute for Extraterrestrial Physics and advanced through clinical collaborations, the PHLAS device represents a fusion of cutting-edge technology with dermatological care.

Julia Zimmermann, PD, PHD's innovative cold plasma technology for acne treatment, developed through extensive research, promises effective results for clearer skin.

Revolutionizing Acne Treatments and Skin Care with Cold Plasma Technology

The cold atmospheric plasma technology, particularly using surface micro-discharge (SMD), has been rigorously studied since 2009. Research from the University Clinic of Regensburg and Dermatest demonstrated strong efficacy in inactivating acne-causing bacteria like Cutibacterium acnes. Clinical trials across Europe have supported PHLAS’s benefits for acne-prone skin, including reduced redness, refined pores, and fewer blemishes—all with a strong safety profile.

Developing PHLAS for at-home use, however, presented substantial challenges. Early prototypes were bulky and used complex systems like argon gas and microwave technology. To create a compact, consumer-friendly version, the team miniaturized components and engineered a safe, high-voltage system internally, necessitating custom electronics. But Zimmermann emphasized the biggest hurdle was public unfamiliarity.

“The biggest challenge is that nobody knows cold plasma,” she noted. “Nobody knows what it is, and we have to go out and explain what a cold plasma is to everybody. Nobody knows the benefits.”

PHLAS is unique among skincare devices, according to Zimmermann. Unlike most creams or liquids, plasma, a partially ionized gas, can penetrate pores deeply without additives. It mimics immune system responses, offering a natural, non-invasive treatment alternative. Zimmermann positions it as a professional-grade technology adapted for personal use. For dermatologists and clinicians, Zimmermann recommends PHLAS for patients struggling with acne, redness, and skin inflammation. The device is hygienic with exchangeable tips and designed for daily use after normal cleansing.

Looking ahead, terraplasma and hyped about science are launching PHLAS to the US market 

. Future innovations may include plasma-compatible creams to enhance treatment absorption, which aligns with Zimmermann’s broader vision of revolutionizing skincare through science.

Julia Zimmermann, a biophysicist and CEO of terraplasma, has developed the PHLAS device, a cold plasma skincare technology. Originating from research at the Max-Planck-Institute, PHLAS effectively targets acne-causing bacteria and improves skin conditions. Despite initial challenges in miniaturizing the device for home use, PHLAS offers a professional-grade, non-invasive treatment option. It penetrates deeply without additives, mimicking immune responses. Zimmermann aims to educate the public on cold plasma benefits and plans to launch PHLAS in the US market, with future innovations in plasma-compatible skincare products.

“When it comes to oral antibiotics, one of the topics I focused on is the fact that antibiotic stewardship is needed. I also like to say that we are honorary gastroenterologists in dermatology because the antibiotics we prescribe affect the gut. We know that the gut microbiome is so important to human health,” said Christopher Bunick, MD, PhD, in an interview at the 

2025 American Academy of Dermatology (AAD) Annual Meeting

Bunick, associate professor of dermatology and translational biomedicine at Yale School of Medicine in New Haven, Connecticut, and 

’ Editor in Chief, presented “Updates on Antibiotics for Acne and Rosacea” at the annual meeting.

In his presentation, Bunick reviewed the evolving role of antibiotics in acne management. His presentation focused on the importance of antibiotic stewardship while outlining the latest recommendations from the 

Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.

Acne

Latest News